CLEC2D

Across TCGA pan-cancer cohorts, CLEC2D RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of CLEC2D’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where CLEC2D RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CLEC2D is over-expressed in tumor, although a few such as COAD and UCEC show the opposite, repressed pattern.

KIRC, KIRP, and COAD are the cancer types where CLEC2D tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CLEC2D RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	IV	+1.490	<.001	11	view →
KIRP	All	All	+0.519	.007	7	view →
COAD	All	All	−0.423	<.001	7	view →
UCEC	All	All	−0.773	<.001	6	view →
HNSC	All	All	+0.356	.007	5	view →
STAD	All	All	+0.645	.011	4	view →
LIHC	Female	All	+0.470	.006	4	view →
BRCA	All	All	+0.259	.014	4	view →
CHOL	All	All	+1.513	<.001	3	view →
THCA	All	IV	+1.465	.010	3	view →
LUAD	All	All	+0.421	.006	2	view →
KICH	All	All	−0.311	.012	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

CLEC2D–KIRC

Open the KIRC breakdown →